Loncastuximab tesirine-lpyl (Zynlonta)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Zynlonta · Reconstitution and dilution
- Preparation
- Reconstitute each vial with 2.2 mL sterile water for injection (5 mg/mL). Add the calculated volume to a 50 mL bag of 5% dextrose.
- Administration and handling
- Infuse over 30 minutes using a dedicated line and a low-protein-binding 0.2- or 0.22-micron filter.
Product and source details
ADC Therapeutics America, Inc. · BLA761196
Product NDC: 79952-110
SPL effective 2026-06-12 | SPL version 15. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.